Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

<table>
<thead>
<tr>
<th>Anaesthetics &amp; Muscle Relaxants</th>
<th>Anticonvulsants</th>
<th>Antibacterials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DOR</strong></td>
<td><strong>DOR</strong></td>
<td><strong>DOR</strong></td>
</tr>
<tr>
<td><strong>DOR</strong></td>
<td><strong>DOR</strong></td>
<td><strong>DOR</strong></td>
</tr>
<tr>
<td><strong>DOR +</strong></td>
<td><strong>DOR +</strong></td>
<td><strong>DOR +</strong></td>
</tr>
<tr>
<td><strong>1/2TF</strong></td>
<td><strong>1/2TF</strong></td>
<td><strong>1/2TF</strong></td>
</tr>
<tr>
<td><strong>ETF</strong></td>
<td><strong>ETF</strong></td>
<td><strong>ETF</strong></td>
</tr>
<tr>
<td><strong>EVR</strong></td>
<td><strong>EVR</strong></td>
<td><strong>EVR</strong></td>
</tr>
<tr>
<td><strong>ETR</strong></td>
<td><strong>ETR</strong></td>
<td><strong>ETR</strong></td>
</tr>
<tr>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
</tr>
<tr>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
</tr>
<tr>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
</tr>
<tr>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
</tr>
<tr>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
</tr>
<tr>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
<td><strong>NVP</strong></td>
</tr>
</tbody>
</table>

**Key to abbreviations**

- **DOR**: Doravirine (Pitolisant®)
- **DOR +**: Doravirine + Lamivudine + Tenofovir-OF
- **1/2TF**: Tenofovir (60mg) (Sustiva® or Stocrin®)
- **ETF**: Efavirenz (Intensé® or Stocrin®)
- **ETR**: Etravirine (Intensé® or Stocrin®)
- **NVP**: Nevirapine (Viramune®)
- **EVR**: Efavirenz (EVL®)
- **RIP**: Rilpivirine (Eduride®)
- **RPI**: Rilpivirine + Dolutegravir (Juluza®)
- **RPV**: Rilpivirine + Emtricitabine + Tenofovir alafenamide (Dovefly®)
- **RPV +**: Rilpivirine + Dolutegravir (Juluza®) + Tenofovir alafenamide (Dovefly®)
- **RPV + DTG**: Rilpivirine + Dolutegravir (Juluza®) + Tenofovir alafenamide (Dovefly®) + Dolutegravir (Juluza®)

**Key to symbols**

- **●**: These drugs should not be coadministered
- **△**: Potential interaction - may require dose monitoring, alteration of drug dosage or timing of administration
- **▲**: Potential interaction likely to be of weak intensity. Additional actionmonitoring or dosage adjustment is unlikely to be required
- **☆**: No clinically significant interaction expected

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Unit, 1st Floor Block H, 70 Princess Dale, LIVERPOOL, L69 3SF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication when arising from negligence, omissions or inaccuracies in information therefrom. The University of Liverpool expressly excludes liability for errors, omissions or inaccuracies to the fullest extent permitted by law.
<table>
<thead>
<tr>
<th>Key to abbreviations</th>
<th>Key to symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOR</td>
<td>These drugs should not be coadministered</td>
</tr>
<tr>
<td>DOR +</td>
<td>Potential interaction — may require dose monitoring, alteration of drug dosage or timing of administration</td>
</tr>
<tr>
<td>TDF + TDF 3TC</td>
<td>Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required</td>
</tr>
<tr>
<td>ETR</td>
<td>No clinically significant interaction expected</td>
</tr>
</tbody>
</table>

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

© Liverpool Drug Interaction Group, University of Liverpool. Pharmacology Research Laboratory, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3CF
We aim to ensure that information is accurate and up-to-date, but cannot accept responsibility for any errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

**Interactions with NNRTIs**

<table>
<thead>
<tr>
<th>Anticonvulsants</th>
<th>Antifungals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td></td>
</tr>
<tr>
<td>Clonazepam</td>
<td></td>
</tr>
<tr>
<td>Eslicarbazepine</td>
<td></td>
</tr>
<tr>
<td>Ethosuximide</td>
<td></td>
</tr>
<tr>
<td>Gabapentin</td>
<td></td>
</tr>
<tr>
<td>Lacosamide</td>
<td></td>
</tr>
<tr>
<td>Lamotrigine</td>
<td></td>
</tr>
<tr>
<td>Levetiracetam</td>
<td></td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
</tr>
<tr>
<td>Pregabalin</td>
<td></td>
</tr>
<tr>
<td>Primidone</td>
<td></td>
</tr>
<tr>
<td>Tiagabine</td>
<td></td>
</tr>
<tr>
<td>Topiramate</td>
<td></td>
</tr>
<tr>
<td>Valproate (Divalprox)</td>
<td></td>
</tr>
<tr>
<td>Vigabatrin</td>
<td></td>
</tr>
<tr>
<td>Zonisamide</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antidepressants</th>
<th>Antihistamines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agomelatine</td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td></td>
</tr>
<tr>
<td>Biphenylin</td>
<td></td>
</tr>
<tr>
<td>Citalopram</td>
<td></td>
</tr>
<tr>
<td>Clomipramine</td>
<td></td>
</tr>
<tr>
<td>Desipramine</td>
<td></td>
</tr>
<tr>
<td>Doxepin</td>
<td></td>
</tr>
<tr>
<td>Duloxetine</td>
<td></td>
</tr>
<tr>
<td>Eslicarbazepine</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td></td>
</tr>
<tr>
<td>Imipramine</td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td></td>
</tr>
<tr>
<td>Maprotiline</td>
<td></td>
</tr>
<tr>
<td>Manserin</td>
<td></td>
</tr>
<tr>
<td>Mirtazapine</td>
<td></td>
</tr>
<tr>
<td>Nefazodone</td>
<td></td>
</tr>
<tr>
<td>Norbuprenorphine</td>
<td></td>
</tr>
<tr>
<td>Paroxetine</td>
<td></td>
</tr>
<tr>
<td>Phenelzine</td>
<td></td>
</tr>
<tr>
<td>Reboxetine</td>
<td></td>
</tr>
<tr>
<td>Sertraline</td>
<td></td>
</tr>
<tr>
<td>Tranxylociprine</td>
<td></td>
</tr>
<tr>
<td>Trazodone</td>
<td></td>
</tr>
<tr>
<td>Trimeprazine</td>
<td></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td></td>
</tr>
<tr>
<td>Voriconazole</td>
<td></td>
</tr>
</tbody>
</table>

**Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required.**

**Potential interaction — may require dose monitoring, alteration of drug dosage or timing of administration.**

**No clinically significant interaction expected.**

For personal use only. Not for distribution. For prescription use only. Not for distribution. For personal use only. Not for distribution.
### Interactions with NNRTIs

**Antivirals**
- Aciclovir
- Adenosine
- Amantadine
- Cidofovir
- Didanosine
- Emtricitabine
- Famciclovir
- Foscarnet
- Ganciclovir
- Ganciclovir/Foscarnet
- Ledipasvir/Sofosbuvir
- Ombitasvir/Paritaprevir
- Ombitasvir/Paritaprevir + Dasabuvir
- Oseltamivir
- Pimozide
- Ribavirin
- Rimantadine
- Sofosbuvir
- Sofosbuvir/Velpatasvir
- Sofosbuvir/Velpatasvir/Voxilaprevir
- Telbivudine
- Tenofovir alafenamide (F/TAF)
- Valaciclovir
- Zanamivir

**Calcium Channel Blockers**
- Amiodipine
- Dilazepine
- Felodipine
- Nicardipine
- Nifedipine
- Nisoldipine
- Nitrergic
- Verapamil

**Beta Blockers**
- Atenolol
- Bisoprolol
- Carvedilol
- Metoprolol
- Nebivolol
- Oxpenolidol
- Pindolol
- Propranolol
- Timolol

**Bronchodilators**
- Albuterol
- Aminophylline
- Formoterol
- Glycopyrronium bromide
- Indacaterol
- Ipratropium bromide
- Montelukast
- Olodaterol
- Rotfumilast
- Salbutamol
- Salmeterol
- Theophylline
- Tiotropium bromide
- Umeclidinium bromide
- Vianterol

**Key to abbreviations**
- DOR = Dolutegravir (Pillar®)
- DRV = Darunavir (Pillar®)
- ETV = Etravirine (Silvabe® Stocrin®)
- FDC = Fixed-Dose Combinations
- TDF + FTC = Emtricitabine + Tenofovir Disoproxil Fumarate
- TDF + FTC (Sustiva® Stocrin®)
- TDF + FTC (Truvada®)
- TDF = Tenofovir Disoproxil Fumarate
- TDF + FTC = Tenofovir alafenamide (Gilead®)

**Key to symbols**
- These drugs should not be coadministered
- Potential interaction - may require dose monitoring, alteration of drug dosage or timing of administration
- Potential interaction likely to be of weak intensity. Additional action monitoring or dosage adjustment is unlikely to be required
- No clinically significant interaction expected

---

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

---

Visit www.hiv-druginteractions.org for full information and further updates.
### Contraceptives/HRT
- Desogestrel (COC)
- Desogestrel (POP)
- Drospirenone (COC)
- Drospirenone (HRT)
- Dydrogesterone (HRT)
- Estradiol
- Ethinylestradiol
- Etynodiol (implant)
- Etynodiol (vaginal ring)
- Gestodene (COC)
- Levonorgestrel (COC)
- Levonorgestrel (emergency contraception)
- Levonorgestrel (implant)
- Levoestriol (IUD)
- Levonorgestrel (POP)
- Medroxyprogesterone (depot injection)
- Medroxyprogesterone (oral)
- Norethisterone (patch)
- Norethisterone (Norethynodrel) (COC)
- Norethisterone (Norethynodrel) (HRT)
- Norethisterone (POPA)
- Norgestimate (COC)
- Norgestrel (COC)
- Norgestrel (HRT)

### Erectile Dysfunction Agents
- Avanafil
- Sildenafil (Erectile Dysfunction)
- Tadalafil (Erectile Dysfunction)
- Vardenafil

### Gastrointestinal Agents
- Alleloer
- Antacids
- Biacetyl
- Cimetidine
- Cisapride
- Desacloprazole
- Esomeprazole
- Famotidine
- Lactulose
- Lansoprazole
- Loperamide
- Meclozine
- Omeprazole
- Pantoprazole
- Prucalopride
- Rabeprazole
- Ranitidine
- Sereno

### Gastrointestinal Agents (anti-emetics)
- Aprepitant
- Dolasetron
- Domperidone
- Ondansetron
- Granisetron
- Metoclopramide
- Ondansetron
- Prochlorperazine

### Herbs/Supplements/Vitamins
- African potato
- Aloe vera
- Ascorbic Acid (vitamin C) [alone]
- Ascorbic Acid [in multivitamins]
- Calcium supplements
- Cat's claw (Urcana tomentosa)
- Colecalciferol (vitamin D3) [alone]
- Colecalciferol [in multivitamins]
- Cubeb pepper (Piper cubeba)
- Cyanocobalamin (alone)
- Cyanocobalamin [in multivitamins]
- Echinacea
- Eucalyptus globulus
- Ferrous fumarate
- Folic acid [alone]
- Folic acid [in multivitamins]
- Garlic
- Ginger
- Ginkgo biloba
- Goldenseal root (Hydrastis canadensis)
- Grapefruit juice
- Hops (Humulus lupulus)

### Key to abbreviations
- DOR + Doravirine (Preluent)
- DOR + Doravirine + Lamivudine + Tenofovir-DF (Delvitec)
- FTC + TDF (Delavite)
- RPV + F/TAF
- RPV + Emtricitabine + Tenofovir alafenamide (Dovato)
- ETR (Elate)

### Key to symbols
- These drugs should not be coadministered
- Potential interaction – may require dose monitoring, alteration of drug dosage or timing of administration
- Potential interaction likely to be of weak intensity. Additional actionmonitoring or dosage adjustment is unlikely to be required
- No clinically significant interaction expected

---

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.
### Key to symbols

- These drugs should not be coadministered
- Potential interaction - may require dose monitoring, alteration of drug dosage or timing of administration
- Potential interaction likely to be of weak intensity. Additional monitoring or dosage adjustment is unlikely to be required
- No clinically significant interaction expected

---

**Interactions with NNRTIs**

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

<table>
<thead>
<tr>
<th>Key to abbreviations</th>
<th>DOR</th>
<th>DOR +</th>
<th>RTV</th>
<th>ETG</th>
<th>NVP</th>
<th>DRV</th>
<th>RPIV</th>
<th>DRV + RTV</th>
<th>TP(\alpha) + ETG</th>
<th>NVP</th>
<th>DRV + RPIV</th>
<th>TP(\alpha) + RPIV</th>
<th>F/TAF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DOR</strong></td>
<td><strong>DOR +</strong></td>
<td>RTV</td>
<td>ETG</td>
<td>NVP</td>
<td>DRV</td>
<td>RPIV</td>
<td>DRV + RTV</td>
<td>TP(\alpha) + ETG</td>
<td>NVP</td>
<td>DRV + RPIV</td>
<td>TP(\alpha) + RPIV</td>
<td>F/TAF</td>
<td></td>
</tr>
<tr>
<td><strong>Antiprotozoal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antihistaminic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antimicrobial</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-infective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-inflammatory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-platelet</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antituberculosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antiviral</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glucocorticoid</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tocopherol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Drug categories**

**DOR**: Dolutegravir (Felside\(\alpha\))

**RTV** (Ritonavir (Eldur\(\alpha\))):

**ETG** (Efavirenz (Sustiva\(\alpha\))):

**NVP** Nevirapine (Viramune\(\alpha\))

**RPIV** Rilpivirine (Eduride\(\alpha\))

**TP\(\alpha\)** (Telecyte\(\alpha\))

**TP\(\alpha\) + ETG**

**NVP** Nevirapine (Viramune\(\alpha\))

**TP\(\alpha\) + RPIV** Rilpivirine + Eduride\(\alpha\)

**NVP** Nevirapine (Viramune\(\alpha\))

**TP\(\alpha\) + RPIV** Rilpivirine + Eduride\(\alpha\)

**NVP** Nevirapine (Viramune\(\alpha\))

**TP\(\alpha\) + RPIV** Rilpivirine + Eduride\(\alpha\)

---

**Key to abbreviations**

**DOR**: Dolutegravir (Felside\(\alpha\))

**DOR +** Dolutegravir + Lamivudine + Tenofovir-DF (Delvite\(\alpha\))

**TP** (Telecyte\(\alpha\)) + TDF (Delvite\(\alpha\))

**TP** (Telecyte\(\alpha\)) + EFV (Elduride\(\alpha\))

**TP + ETG** (Telecyte\(\alpha\)) + Efavirenz (Sustiva\(\alpha\))

**TP + NVP** (Telecyte\(\alpha\)) + Nevirapine (Viramune\(\alpha\))

---

**Key to symbols**

- These drugs should not be coadministered
- Potential interaction - may require dose monitoring, alteration of drug dosage or timing of administration
- Potential interaction likely to be of weak intensity. Additional monitoring or dosage adjustment is unlikely to be required
- No clinically significant interaction expected

---

**Notes**

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its authors or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly excludes liability for errors, omissions or inaccuracies to the fullest extent permitted by law.